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Erythropoietin (EPO) is not only a hormone that promotes erythropoiesis but also
has a neuroprotective effect on neurons attributed to its known anti-apoptotic action.
Previously, our group has demonstrated that recombinant-human EPO (rHu-EPO) can
protect neurons and recovery motor activity in a chemical focal brain hypoxia model
(Merelli et al., 2011). We and others also have reported that repetitive seizures can mimic
a hypoxic- like condition by HIF-1α nuclear translocation and high neuronal expression
P-gp. Here, we report that a single 20-min status epilepticus (SE) induces P-gp and
EPO-R expression in cortical pyramidal neurons and only P-gp expression in astrocytes.
In vitro, excitotoxic stress (300 µM glutamate, 5 min), can also induce the expression
of EPO-R and P-gp simultaneously with both HIF-1α and NFkB nuclear translocation in
primary cortical neurons. Primary astrocytes exposed to chemical hypoxia with CoCl2
(0.3 mM, 6 h) increased P-gp expression as well as an increased efflux of Rhodamine
123 (Rho123) that is a P-gp substrate. Tariquidar, a specific 3er generation P-gp-blocker
was used as an efflux inhibitor control. Astrocytes treated with rHu-EPO showed a
significant recovery of the Rho123 retention in a similar way as seen by Tariquidar,
demonstrating for first time that rHu-EPO can inhibit the P-gp-dependent efflux activity.
Taking together, these data suggest that stimulation of EPO depending signaling system
could not only play a central role in brain cell protection, but this system could be a new
tool for reverse the pharmacoresistant phenotype in refractory epilepsy as well as in
other pharmacoresistant hypoxic brain diseases expressing P-gp.
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INTRODUCTION
Erythropoietin receptor (EPO-R) has been detected in several
non-hematopoietic mature cells, usually induced by hypoxic
conditions. Irrespective to the erythropoietic stimulation,
erythropoietin (EPO) action on EPO-R plays a central
role inducing a broad range of cellular responses aimed
to preserve the integrity of stressed cells and to protect
different cells from hypoxia or other stress signaling (Lappin,
2003). EPO-R has been classically regarded as the EPO main
receptor, however, recent data shows that EPO can be active
through canonical EPO-R or non-canonical receptors such
as Ephrin receptors or transient receptor potential vanilloid
(TRPV) channels (see for revision Bond and Rex, 2014;
Malik and Di Benedetto, 2018).
The prototypical hypoxia response in eukaryotic cells is the
activation of several transcription (HIF-1α factors, particularly
the hypoxia-inducible factor 1α), which induces the expression
of a wide spectrum of pro-survival genes, including both
EPO and EPO-R (Semenza, 2000; Ruscher et al., 2002). In
spite of the fact that this robust mechanism is universal
for all cell types under similar hypoxic conditions, EPO and
EPO-R expression levels are not similar for all cell types
from the same tissues (Semenza, 2000). Additionally, HIF-
1α stabilization is also detected stimuli even under normoxic
condition. For example, the redox-sensitive transcription factor
NF-κB (nuclear factor kappa-B) usually involved in inflammation
and immune responses (Liu et al., 2017), can also bind to a
distinct element in the proximal promoter of the HIF-1α gene
(Görlach and Bonello, 2008).
Both transcription factors HIF-1α and NF-κB, can activate
MDR-1/ABCB1gene inducing the expression of P-glycoprotein
(P-gp). After their discovery in chemotherapeutic resistant
cancer (Juliano and Ling, 1976), P-gp was the first ABC-
transporter described to be related with drug-resistant epilepsy
as well as in brain and heart hypoxia-ischemia (Tishler
et al., 1995; Lazarowski et al., 1999, 2004, 2005, 2007;
Ramos et al., 2004). In hypoxic conditions, HIF-1α is the
master transcriptional regulator of cellular and developmental
response to oxygen deprivation in all tissues. Consequently,
the stabilization and nuclear translocation of HIF-1α is
observed and a wide spectrum of genes are up-regulated,
that include the EPO-R and P-gp (Comerford et al., 2002;
Aviles-Reyes et al., 2010; Merelli et al., 2011; Semenza,
2014; Auzmendi et al., 2018). Furthermore, seizures generate
conditions producing acute brain hypoxia and ischemia followed
by inflammation. Some common sequential events including
neurotoxicity, depolarization, inflammation and apoptosis have
been observed, including the phosphatidylserine exposition
on the outer plasmatic membrane (Bateman et al., 2008;
Moseley et al., 2010).
A large body of evidence has demonstrated that EPO
has several extra-hematopoietic protective effects to a wide
spectrum of hypoxic cells and tissues, including cardiovascular,
immunity and nervous systems. In Central nervous system
(CNS), EPO promotes neuronal development, prevents cell
death of damaged neurons, and improves learning and memory
(Morishita et al., 1997; Lu et al., 2005; Al-Qahtani et al.,
2014; Badowska-Kozakiewicz et al., 2017). Interestingly, several
conditions such as hypoxic, traumatic, or inflammatory stresses
also can induce P-gp overexpression (Kooij et al., 2012; de Lemos
et al., 2013; Jullienne et al., 2016; Willyerd et al., 2016).
In an experimental brain ischemic model previously
developed by our group, direct brain intracortical CoCl2
injection induced HIF-1α nuclear translocation and
high EPO-R and P-gp expression in neurons (Caltana
et al., 2009). In this experimental paradigm, intranasal
recombinant human EPO (rHu-EPO) administration had
not only an effective therapeutic response by recovery
of motor activity, but also had a neuroprotective action
at cellular level on hypoxic damaged neurons (Merelli
et al., 2011). However, the potential effect of EPO on
the efflux activity of P-gp in cells of CNS has not been
investigated yet.
Since hypoxia and epilepsy shared a partially similar
signaling pathways, we hypothesized that excitotoxic stress
could induce overexpression of both EPO-R and P-gp. Here,
we evaluated in vivo and in vitro the neuronal and glial
induced-expression of P-gp and EPO-R after excitotoxicity.
Additionally, we investigated the effect of rHu-EPO over
the P-gp activity. Our results support the idea of the
excitotocixity could mimic to hypoxia by inducing EPO-R
expression thus allowing the therapeutic with rHu-EPO in
refractory epilepsy and other pathological stated where P-gp
has a major role.
MATERIALS AND METHODS
Ethics Statement
All procedures involving animals and their care were conducted
in accordance with our institutional guidelines, which comply
with the NIH guidelines for the Care and Use of Laboratory
Animals and the principles presented in the Guidelines for the
Use of Animals in Neuroscience Research by the Society for
Neuroscience, and were approved by the CICUAL committee
of the School of Medicine University of Buenos Aires (Res. Nr.
1278/2012). All efforts were made to minimize animal suffering
and to reduce the number of animals used.
Reagents
Cell culture reagents were obtained from Invitrogen Life
Technologies (Carlsbad, United States). Fetal calf serum (FCS)
was purchased from Natocor (Córdoba, Argentina). Antibodies
were purchased from Santa Cruz (rabbit polyclonal anti-p65
cat# SC-8008 and polyclonal rabbit anti-Epo-R), Abcam (mouse
polyclonal anti-P-gp, cat# ab3083), and Sigma (polyclonal
rabbit antiHIF-1α cat# HPA001275). Poly-L-lysine, DAPI (4′6-
diamidino-2-phenylindole), Rhodamine 123 (Rho123), 3rd
generation P-gp inhibitor Tariquidar and other chemicals were
obtained from Sigma (United States). Fluorescent secondary
antibodies were purchased from Jackson Immunoresearch
(United States). Microscopic images were taken using an
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Olympus IX- 81 microscope equipped with a DP71 camera
(Olympus, Japan).
Cell Culture and Treatments. Neuronal
Culture
Wistar rat embryos of 17 days (E17) were used for primary
cortical neurons culture as previously described (Villarreal et al.,
2011). Briefly, embryos were removed from the maternal uteri,
brains were surgically removed and cortices were separated
under sterility. After a treatment with 0.25% trypsin cortical
neurons were mechanically dissociated through a Pasteur pipette.
Neurons were placed in a plastic multi-well plate coated
with poly-L-lysine. Cells were maintained with NeuroBasal
(Invitrogen) supplemented with 2% B27 (Invitrogen) and 0.5 mM
glutamine. After 7 days in vitro (7DIV), neurons were exposed
to excitotoxicity during 5 min with 300 µM glutamate at.
Then, neurons were washed and medium was replaced by
supplemented NeuroBasal. After 24 h of recovery, neurons were
fixed 4% paraformaldehyde plus 4% sucrose in PBS pH 7.2 for
15 min at room temperature.
Glial Culture
Primary cortical glial cell cultures were obtained from 3 to 5 post-
natal day rats as described previously (Rosciszewski et al., 2018).
Briefly, brains were separated from the skull and meninges were
removed. Cortices were dissected and mechanically disrupted
with in Dulbecco’s modified Eagle medium (DMEM). After
centrifugation dissociated glial cells were resuspended in DMEM
supplemented with 10% FCS, 2 mM L-glutamine, and 100 µg/ml
penicillin-streptomycin. Then, glial cells were plated in 96-multi-
well plate and were incubated at 37◦C and 5% CO2 for 7 days until
reaching the confluence and medium was replaced every 48 h.
Status Epilepticus (SE) Protocol
Status epilepticus was induced in 230–250 g Wistar male rats
using the lithium -pilocarpine paradigm as previously described
(Rossi et al., 2013, 2017). Briefly, sodium lithium chloride was
injected (127 mg/kg- i.p), and 20 h later pilocarpine (30 mg/kg,
i.p.), were administrated. Severity of seizures were evaluated
according to the Racine scale (Racine, 1972) and the rats were
considered to have suffered SE when remained more than 5 min
with myoclonic and/or tonic-clonic generalized seizures (Racine
stages 4 and 5). After 20 min, SE was stopped applying dizepam
(20 mg/kg i.p.). All animals were kept under intense care during
the initial 24 h to improve animal recovery from seizures and
to maintain hydration and feeding. A volume of 0.5 ml of saline
was administered every 12 h to maintain hydration. The control
non-convulsive group was injected with a lithium-saline solution.
After that initial critical 24 h period, animals were routinely
monitored until sacrificed at 15 days post-SE (15 DPSE).
Animal Fixation and
Immunohistochemistry
At 15 DPSE, animals were deeply anesthetized with
ketamine/xylazine (90/10 mg/kg i.p.), and sacrificed by
intracardiac perfusion with 4% paraformaldehyde in phosphate
buffer as previously described (Rossi et al., 2013). Frozen brains
were cut into 30-µm thick sections and were cryopreserved in
a 0.1 M phosphate buffer saline (PBS) containing 20% glycerol
and 30% ethylene-glycol. The sections were stored at −20◦C
until use. For immunohistochemistry, sections were washed with
PBS and permeabilized with 1% Triton X-100 in PBS (PBS-X)
at room temperature. The unspecific binding was prevented by
1 h incubation with 10% normal goat serum (NGS) in PBS-X at
room temperature. Then sections were incubated with primary
antibodies diluted in PBS-X plus 3% NGS at 4◦C during 48 h.
Anti EPO-R and anti-P-gp antibodies were used at 1:400 dilution.
After washing, sections were incubated with the appropriate
fluorescent secondary antibodies at 1:800 dilution for 4 h at room
temperature. Secondary antibodies fluorochromes were Alexa
488 or Alexa 594 (Jackson Immunoresearch). Rat speen sections
(10 µm) were used for testing EPO-R immunoreactivity.
Primary Culture Immunocytochemistry
Neuronal or glial primary cultures were fixed with 4%
paraformaldehyde plus 4% sucrose in PBS pH 7.2 for 15 min
at room temperature. Only when immunocytochemistry
was performed against intracellular epitopes, neurons were
permeabilized with PBS-X for 15 min. Unspecific binding
was blocked by a 30 min incubation with 5% NGS in PBS at
room temperature. Then, primary antibody incubation was
performed 24 h at 4◦C in a solution containing the respective
antibody in 5% NGS in PBS. After 3 washes in PBS, cells
were incubated with the appropriate fluorescent secondary
antibodies (Alexa 488 or Alexa 594) for 2 h at room temperature.
Primary antibodies were used 1:400 dilution while secondary
antibodies were used 1:800. Nuclear counterstaining was
routinely done with DAPI.
P-gp Activity Assay
Cortical glial cultures were used to study the effect to
rHu-EPO over P-gp activity. Astrocytes were exposed to
chemical hypoxia by incubation with 0.3 mM CoCl2 in
complete DMEM for 6 h at 37◦C. Following chemical
hypoxia induction, glial cells were washed and then medium
was replaced complete serum free DMEM containing rHu-
EPO 30–300 IU/ml for 30 min. Then, cells were allowed
to load Rho123 by incubating them in serum free DMEM
containing 1 µM Rho123 for 5 min. After several washes,
we determined the Rho123 retention with a fluorescence
microscope. Tariquidar 5 µM was used as a specific blocker of
P-gp. rHu-EPO was prepared from a stock solution of 106 IU/ml
in dimetilsulfoxide (DMSO).
Quantification and Statistical Analysis
Morphometrical and densitometric analysis were performed with
ImageJ (NIH) and statistical analysis was done with Graph Pad
prism software. The area covered by the immunostained cells
and the fluorescence intensity were evaluated. After checking the
normal distribution of the data, differences were analyzed by one-
way ANOVA and Student Newman Keuls post-test comparison
or by two tailed Student t-test.
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FIGURE 1 | P-gp and EPO-R increased expression after status epilepticus. (A) Representative images of EPO-R and P-gp immunostaining in brain cortical sections
of rats by 15 days post-SE (DPSE). (A) Low magnification images of the entire cortical layers (bar = 0.5 mm). (B) Larger magnification of the dashed squares from A.
(bar = 0.1 mm). Cyan arrow heads represent pyramidal cortical neurons expressing P-gp. (C) The graphs show the quantification of the immunostaining showed as
the number of neurons per field that express P-pg or EPO-R. Alternatively, the area covered by P-gp staining also shows a significant increase after SE. We analyzed
five representative images per animal (three animals per treatment) and differences were analyzed by two tailed Student t-test that showed a significance level of
p < 0.001 (∗∗∗). (D) Sections of spleen as a positive control of EPO-R antibody binding (bar = 0.5 mm).
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FIGURE 2 | Excitotoxic stress promotes the P-gp and EPO-R expression in vitro in primary cortical neurons. Representative images showing the neuronal
expression of P- gp (green), EPO-R (red) and nuclei (blue) in control conditions and after exposing neurons to glutamate excitotoxicity by 5 min 300 uM glutamate.
Merge show the co-localization while A1 and A2 are expanded view of neurons that co-localized EPO-R and P-gp. Bar = 50 µm. Note that excitotoxicity induced
EpoR and P-gp expression in cortical neurons. The graph shows that this excitotoxicity level significantly affects neuronal survival evaluated as nuclear morphologies.
Differences were analyzed by two tailed Student’s t-test that showed a significance level of p < 0.001 (∗∗∗).
RESULTS
Convulsive Stress Promotes the P-gp
and EPO-R Expression
Convulsive stress produced by SE induces a myriad of changes
in gene expression in neurons and glial cells. These alterations
in gene expression and network remodeling are hypothesized
to have a main role in the natural story of epilepsy. Because
seizures produce an acute hypoxic condition, we first studied
if SE was able to induce a long term change in P-gp and
EPO-R expression in vivo. For that purpose, we induced a
single SE and analyzed the P-gp and EPO-R expression by
immunohistochemistry at 1 day post SE. As shown in the
Figures 1A,B, the P-gp and EPO-R expression was increased in
brain cortical glia and neurons after SE. Quantitative analysis
of P-gp immunostained area per field, including glial cells
and neurons, showed a 5-times increase in P-gp expression
(Figure 1C). The number of pyramidal neurons expressing
P-gp was increased about 7 times. Additionally, a 4-times
increase in the number of pyramidal neurons expressing EPO-
R was observed (Figure 1C). EPO-R expression was not
clearly found in cells with astrocytes while P-gp expression
was present in either astrocytes or neurons. Specificity of
EPO-R antibody was tested using spleen sections as positive
control (Figure 1D).
Excitotoxic Stress and P-gp and EPO-R
Expression in vitro
Since the status epilepticus can produce a wide spectrum of
biological responses including hypoxia-ischemic stress, P-gp and
EPO-R could be expressed as a consequence of the hypoxia
rather than the excitotoxic-convulsive stress itself. To separate the
hypoxia from convulsive stress effects we used a primary cortical
neurons culture under normoxia. To mimic the convulsive stress,
neurons were exposed to a brief pulse of excitotoxic glutamate
concentration (0.3 mM). The excitotoxic stimulation significantly
reduced neuronal survival evaluated as the abundance of non-
apoptotic neurons (Figure 2) but surviving neurons expressed
both P-gp and EPO-R (Figure 2).
P-gp and EPO-R genes are known targets of transcription
factors HIF-1α and NF-κB, so we tested whether the
excitotoxicity was able to induce the activation of these
factors. As expected, glutamate pulse induced the stabilization
of HIF-1α and nuclear translocation of both p65 NF-κB subunit
and HIF-1α in primary cortical neurons (Figure 3).
rHu-EPO Inhibit the P-gp Efflux Activity
We have hypothesized that rHu-EPO treatment may have an
effect over the P-gp activity. As a first step to test the rHu-
EPO effects, we designed a functional assay using a glial
mixed culture containing astrocytes and microglia. Both cell
types are easily discriminated by analyzing morphological clues.
Astrocytes are classically seen as star-like shaped cells growing
as a monolayer on the bottom of the tissue culture plate,
while microgliocytes are small rounded-shaped cells usually
growing on top of astrocytic monolayer. Astroglial Rho123
retention was evaluated after chemically CoCl2-induced hypoxia,
and P-gp specific 3rd generation P-gp blocker Tariquidar was
used as positive control of P-gp inhibition. Rho123 is a cell
permeable dye that is also P-gp substrate and thus Rho123-
loaded cells rapidly pump out Rho123 if the P-gp is active.
As shown in Figure 4A, decreased Rho123 retention level
in hypoxic astrocytes was observed, while the treatment of
these cells with 5 M P-gp inhibitor Tariquidar prevented the
Rho123 effluxµ (Figures 4B,D). Interestingly, Rho123 retention
in microglial cells remained unchanged with all treatments
(Figure 4B) due to the absence of Pgp expression in this cell
type. In our conditions chemical hypoxia by CoCl2 did not
produce significant alterations in astrocyte or microglia cell
survival (Figure 4C).
Next, using the same functional assay, we tested the effect
of three rHu-EPO concentrations (30, 100, 300 IU/ml) on P-gp
efflux activity. Again, hypoxic astrocytes showed a decreased
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FIGURE 3 | Nuclear translocation of NF-κB and HIF-1α after excitotoxic
stress. Representative images of 10 DIV primary cortical neurons exposed to
glutamate excitotoxicity (300 µM; 5 min), incubated for 24 h and
immunostained for p65 NF-κB subunit (red) and HIF-1α (green). Nuclear
counterstaining is shown with DAPI. Note the nuclear re-localization of p65
indicating the activation of NF-κB signaling pathway and the increased
immunostaining for HIF-1α from negative in control neurons to be detectable
after excitotoxicity. Bar = 50 µm.
Rho123 retention that was prevented by rHu-EPO treatment, in
a concentration independent manner (Figure 5).
DISCUSSION
In the present study, we reported the simultaneous induction
of P-gp and EPO-R expression in brain cortex after SE-
induced stress. A similar induction was also observed
in vitro when primary cultured neurons where stimulated
with an excitotoxic glutamate pulse, and it was associated
with NF-κB and HIF-1α nuclear translocation. These
translocations are typically associated with the activation of
both hypoxic and inflammatory responses. Since in vitro testing
did not involve oxygen deprivation, the NF-κB/HIF-1α
crosstalk is the most likely explanation for this cross-
stimulation. Specifically, in innate immunity, this crosstalk
has been already demonstrated [Rius et al., 2008; revised in
D’Ignazio et al. (2016)].
Interestingly, as previously observed, other situations induce
simultaneous EPO-R and P-gp expression. We have previously
shown CoCl2 exposure, a chemical compound that inhibit prolyl-
hydroxylase and thus stabilizes HIF-1α, induce both P-gp and
EPO-R expression (Merelli et al., 2011). This evidence, together
with our present results, suggests that severe convulsive stress
can induce the expression of a wide spectrum of HIF-1α and
NF-κB-dependent genes, mimicking hypoxic or inflammatory
conditions (Semenza, 2000; Ruscher et al., 2002).
Canonical and Non-canonical Response
to EPO
The high EPO-R expression induced by these convulsive
stress signals provides an opportunity for the pharmacological
intervention with EPO to seek cell protection. In this regard,
it was demonstrated that EPO can trigger a wide spectrum
of protective effects, including improvement in learning
and memory, promoting CNS development or blocking cell
death in stroke models. EPO-induced intracellular signaling
is mainly mediated by the homodimerization of EPO-R
(Figure 6) followed by the activation of Janus kinase 2
(JAK2) and signal transducer and activator of transcription
5 (STAT5), as well as mitogen- activated protein kinase
(MAPK) and NF-κB (Maiese et al., 2004; Broxmeyer, 2013).
Notably our study illustrates that glutamic acid-stimulated
neurons exhibit NF-κB expression. The NF-κB-seems to
mediate EPO effects depending on the type of cells involved
(Nairz et al., 2012). While EPO activates NF-κB in erythroid
cells, it inhibits this pathway in macrophages, resulting in
decreased production of TNF-alpha and reduced expression of
nitric oxide synthase.
In CNS several EPO non-canonical pathway have been
summarized by Ostrowski and Heinrich (2018). EPO can
activate the JAK pathway through activation of the so
called common beta receptor (βcR) (Brines and Cerami,
2006; Zhang et al., 2014), the orphan cytokine receptor-
like factor 3 (CRLF3) is a type 1 cytokin receptor as
well as thrombopoietin receptor, prolactin receptor and
EPO-R (Boulay et al., 2003). The first evidence of CRLF3
is involved in neuroprotective EPO effect proceed from the
experiments with primary cultures insect neurons. Hahn
et al. (2017) showed that EPO neuroprotective effect against
the hypoxia was loose when they silencing the orthologous
CRFL3. Additionally, experiments performed in neurons of
different insects that do not express EPO-R (Locusta migratoria,
Chorthippus biguttulus, and Tribolium castaneum) revealed
Epo-mediated neuroprotection throughout JAK/STAT activation
(Heinrich et al., 2017).
Working with ovarian carcinoma cells, Pradeep et al.
(2015), shown that EPO was recognized by Ephrin receptor
B4 (EphB4) which is well known through its interaction
with Ephrin B2 (EphB2). Furthermore, EphB2 also actives
the EPO-R in the same cells. In contrast to the canonical
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FIGURE 4 | Functional assay for determine the P-gp activity after hypoxia. (A) Schematic procedure for induction and determination of P-gp activity through the
Rhodamine 123 efflux. (B) Representative images of the glial cell cultured under control (Ctrl), hypoxia (Hx) or tariquidar (Tq) condition. Phase contrast images were
used to check the condition of the culture and were obtained from the same field as the Rho 123 fluorescence images. (C) Quantitative analysis of the number of
astrocytes and microglia under hypoxia. (D) Fluorescence quantification of the functional assay. Differences were analyzed by one-way ANOVA and Bonferroni
post-test with a significance level of the p < 0.05 (∗) and p < 0.001 (∗∗∗) vs. the control or p < 0.001 (&&&) vs. the hypoxia condition.
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FIGURE 5 | hr-EPO blocks the activity of the P-gp. (A) Images of Rhodamine 123 retention with different treatments (primary magnification x20).
(B) Quantification of the rHu-EPO effect. Differences were analyzed by ANOVA with a significance level of p < 0.001 (∗∗∗compared to control and &&&compared to
hypoxia treatment).
pathway (EPO/EPO-R induced-JAK2/STAT5 activation),
the binding of EPO to EphB4 promotes the activation of
Src kinase and STAT3. In CNS, EphB4 is expressed in
neurons, astrocytes, and endothelial cells, but have “no-
JAK” tyrosine kinase activity involved (Ashton et al., 2012;
Todd et al., 2017) and its stimulation with EphB2 has
been demonstrated to regulate the neurogenesis in the
hippocampus. This effect is superimposed with EPO effect,
so the stimulation of EphB4 could explain, at least in part, the
neuroprotective action of EPO.
On the other hand, a new activity of EPO has been recently
reported on several transient receptor potential channels (TRPs)
(Myssina et al., 2003; Danielczok et al., 2017). Some of these
TRPs are related to higher seizure susceptibility (Zheng and
Phelan, 2014; Phelan et al., 2017). Recently it was proposed
that an anticonvulsant action of TRPV1 antagonists could be
mediated through the modulation of glutaminergic systems
(Suemaru et al., 2018) or its relation with pentylenetetrazole
and amygdala-induced kindling models (Shirazi et al., 2014).
Additionally, others report, have linked some TRPs with or P-gp
activity (Ma et al., 2012, 2014; Wang et al., 2015).
Perspectives for rHu-EPO Treatment in
Refractory Epilepsies
In spite the growing availability of new antiepileptic drugs,
pharmacoresistant phenotype remains observed in 30–40%
of patients with epilepsy. In this subset of patients, brain
overexpression of P-glycoprotein and its efflux activity have been
proposed as a main mechanism of refractoriness in epilepsies
(Robey et al., 2008; Feldmann and Koepp, 2016; Tang et al., 2017).
In our hands, EPO effectively reduced the Rho123 efflux
from astrocytes showing an effect that mimic the reached by the
specific P-gp blocker Tariquidar. To this end, we currently cannot
define if EPO is acting directly on P-glycoprotein or indirectly
via the canonical or non-canonical EPO-R. We cannot rule out
either that EPO acts independently of receptor interaction (see
for revision Bond and Rex, 2014; Malik and Di Benedetto, 2018).
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FIGURE 6 | Possible EPO signaling pathway. Schematic representation of the all possible molecular mechanism. Interaction described by bibliography are
represented by solid arrows while other possible target of EPO is represented by dashed arrows.
In addition, it should be considered that our cultures contain
a 20–30% microglia that can be interacting in trans with
astrocytes to mediate EPO effects on P-gp. Seizure burden
induces high expression of P-gp, and hypoxic-insult increased
neuronal expression of EPO-R and P-gp, respectively (Merelli
et al., 2011; Auzmendi et al., 2013). In addition, our present
results show that SE robustly induces both EPO-R and
P-gp in neurons; and that rHu-EPO effectively blocks P-gp-
dependent transport in astrocytes. Under these conditions, rHu-
EPO emerges as a tempting molecule to provide a potential
opportunity to reverse the P-gp-dependent pharmacoresistant
phenotype observed in high percentage of refractory epileptic
cases and other pathological states.
To define whether EPO treatment can be used in refractory
epilepsies, experiments with animal models of pharmacoresistant
epilepsy should be performed. In this way, we should investigate
the EPO administration via to achieve the inhibition of
P-gp and the relationship with the most commonly used
anticonvulsant drugs.
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